Furthermore, since regorafenib has already been approved by the U.S. FDA for the treatments of colon cancer and gastrointestinal stromal tumor [8, 9] utilization of this drug in treating MALT1-related cancers such as ABC-DLBCL should be easily adopted. This evidence concerns the gene MALT1 and gastrointestinal stromal tumor.